Why choose stem cell banking for your family?

Turning to a private stem cell bank gives you the opportunity to collect and preserve your children’s own stem cells (autologous stem cells), should they ever need them in future therapies.

Future Health Biobank specialises in storing HSCs and MSCs found in umbilical cord blood, cord tissue and milk teeth. These are a 100% HLA match to the child they are collected from, and offer a 25% match to their siblings.

One small umbilical cord or tooth sample can yield a high stem cell count for multiple potential uses, if processed and stored by a professional stem cell bank. This can act as a valuable lifeline for decades to come.

ask for consultation

Umbilical cord stem cell

Your baby’s umbilical cord blood is a rich source of precious stem cells. These stem cells have the ability to repair and protect the body from within by transforming (differentiating) into many different types cells within blood and tissue.

Cord blood banking is the process of collecting, processing and storing these cells for use in potential future medical uses. Currently, cord blood stem cells are being used to manage cancerous blood disorders such as leukaemia, blood conditions like Fanconi anaemia and much more.

Cord stem cells are unique to your baby; a 100% HLA match, no fear of the body rejecting them.

There is only one chance to bank your baby’s cord stem cells; the day they are born.

ask for information? more..

Tooth stem cells

One valuable source of stem cells can be found within the pulp of our teeth. Tooth stem cells have the ability to repair tissue cells throughout the body.

Many studies have demonstrated that these cells can be isolated from milk teeth or healthy adult teeth and banked for use in potential future treatments.

Like all cells in our body, stem cells deteriorate with age. This makes stem cells from milk teeth especially valuable because they are younger and healthier. Your child’s tooth stem cells could offer lifelong health protection!

ask for information more…

Clients about us

“We got your contact from the hospital with our doctor. We decided to do this procedure because our first child had leukemia. Sampling at delivery was fast. Everything went well. We are grateful.”

A.K. (34 y)

“I heard about the possibility of stem cell preservation from my girlfriend, who works as a family doctor nurse. While Googling, I reached a firm that provides this service in Estonia. Childbirth proceeded as planned, cells were picked up quickly and professionally. The only thing I regret is that my son, born 3 years ago, has no personal cells in the bank”.

M.K. (31 y)

“I was 8 months pregnant when my husband was reading about the possibility of storing a baby’s stem cells here in Estonia. The decision to take this step came quickly because our family has had both blood cancer and diabetes, for which we read that treatment options are very promising. Of course, we hope we never need the cells. The ELUMUS consultants answered all of our questions, plus information about the clinics where and what can be treated and what studies have been published (I am a medical professional, so evidence-based research is important to me).”

Family L. from Tallinn

Facts

The first successful stem cell transplantation in 1988 – the patient completely cured from Fanconi anemia¹

>20 years hematopoietic stem cells in standard therapy

90,000+ hematopoietic stem cell transplantations worldwide each year²

50,000+ scientific publications about mesenchymal stem cells

300+ diseases currently studied in clinical trials with stem cells

300+ clinics worldwide provide treatment with mesenchymal stem cells

References:

¹ Gluckman, E., et al. “Hematopoietic Reconstitution in a Patient with Fanconi’s Anemia by Means of Umbilical-cord Blood from an HLA-identical Sibling.” Diss. Bone Marrow Transplant Unit, Hôpital Saint-Louis, Paris, France, n.d. Abstract. National Center for Biotechnology Information. U.S.

² One and Half Million Hematopoietic Stem Cell Transplants (HSCT). Dissemination, Trends and Potential to Improve Activity By Telemedicine from the Worldwide Network for Blood and Marrow Transplantation (WBMT). D. Niederwieser et al. Clinical Allogeneic Transplantation: Results| nov.13, 2019